NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 15 February 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice-chair) Present for all items
3. Dr Peter Baker-Gulliver Present for all items
4. Richard Ballerand Present for all items
5. Dr Andrew Champion Present for all items
6. Dr Justin Daniels Present for all items
7. Dr Steve Edwards Present for all items
8. Dr Rita Faria Present for all items
9. Dr Michael Holmes Present for all items
10. Prof. Khalida Ismail Present for all items
11. Dr Fiona MacPherson Smith Present for all items
12. Prof. G.J. Melendez-Torres Items 1 to 6.1.3
13. Dominic Pivonka Present for all items
14. Dr Mohit Sharma Present for all items
15. Alan Thomas Present for all items
16. Dr Roger Whittaker Present for all items

NICE staff present

Henry Edwards, Associate Director Items 1 to 4.3.2

Janet Robertson, Associate Director Items 5 to 6.2.2

Thomas Feist, Project Manager Items 5 to 6.2.2

Jeremy Powell, Project Manager Items 1 to 4.3.2

Alexandra Filby, Heath Technology Assessment Adviser Items 5 to 5.2.2

Mary Hughes, Heath Technology Assessment Adviser Items 6 to 6.2.2

Hannah Nicholas, Heath Technology Assessment Adviser Items 1 to 4.3.2

Cara Gibbons, Heath Technology Assessment Analyst Items 6 to 6.2.2

Emily Leckenby, Heath Technology Assessment Analyst Items 1 to 4.3.2

Sarah Wilkes, Heath Technology Assessment Analyst Items 5 to 5.2.2

Adam Storrow, Business Analyst, RIA Present for all items

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment Items 5 to 6.2.2

Neha Jiandani, Technical Analyst, Commercial Risk Assessment Items 5 to 5.2.2

Ella Livingstone, Technical Analyst, Commercial Risk Assessment Items 1 to 4.3.2

Sarah Bromley, Senior Medical Editor Items 1 to 4.3.2

Ruth Melville, Senior Medical Editor Items 6 to 6.2.2

Benjamin Pearce, Senior Medical Editor Items 5 to 5.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 6.2.2

Catherine Pank, Assistant Project Manager, COT Items 6 to 6.2.2

Lyn Davies, Coordinator, MIP Items 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Laura Kelly, Administrator, COT Items 6 to 6.2.2

Marcia Miller, Administrator, TA Items 5 to 5.2.2

Rumana Zaman, Administrator, TA Items 1 to 4.3.2

External assessment group representatives present

Dolapo Ayansina, Aberdeen HTA Group Items 1 to 4.2.1

Charlotte Kennedy, Aberdeen HTA Group Items 1 to 4.2.1

Graham Scotland, Aberdeen HTA Group Items 1 to 4.2.1

Aline Navega Biz, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Matt Stevenson, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Janette Greenhalgh, Liverpool Reviews, and Implementation Group (LRiG) Items 6 to 6.1.3

James Mahon, Liverpool Reviews, and Implementation Group (LRiG) Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Mary Foss, Patient expert nominated by Short Bowel Survivor and Friends, Items 1 to 4.2.1

Dr Simon Gabe, Consultant in Gastroenterology & Intestinal Rehabilitation, clinical expert nominated by St Mark's hospital, Items 1 to 4.2.1

Dr Susan Hill, Paediatric Gastroenterology Consultant, clinical expert nominated by Takeda UK Limited, Items 1 to 4.2.1

Carolyn Wheatley, Patient expert nominated by Patients on Intravenous and Nasogastric Nutrition Therapy (PINNT), Items 1 to 4.2.1

Professor Samreen Ahmed, Consultant Medical Oncologist, clinical expert nominated by Merck Sharp & Dohme (UK) Ltd, Items 5 to 5.1.3

Prof Peter Clark, Cancer Drug Fund Clinical lead, NHS England Items 5 to 6.2.2

Holly Heath, Patient expert nominated by Breast Cancer Now Items 5 to 5.1.3

David Chuter, Patient expert nominated by Guts UK Charity Items 6 to 6.1.3

Professor Wasat Mansoor, Consultant Medical oncologist, clinical expert nominated by Bristol Myers Squibb, Items 6 to 6.1.3

Dr Elizabeth Smyth, Consultant in Gastrointestinal Oncology, clinical expert nominated by Royal College of Physicians, Items 6 to 6.1.3

External observer

Karen Facey, Rare disease consultant, working with HST and Life Sciences Team, Items 1 to 4.3.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the previous committee meetings held on 7 December 2021 and 18 January 2022.

### Appraisal of teduglutide for treating short bowel syndrome [ID3937]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Takeda UK Limited.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Dr Susan Hill declared financial interests as she has received speaker, lecture and advisory board fees from Takeda and Zealand Pharma in relation to short bowel syndrome (SBS). It was agreed her declaration would not prevent Dr Hill from providing expert advice to the committee.
* Nominated clinical expert Dr Simon Gabe declared financial interests as he has received honorarium from Takeda and Fresenius Kabi in relation to short bowel syndrome (SBS). He also noted that his organisation St Marks are part of international studies with Zealand Pharma and Takeda in relation to comparator drugs glepaglutide and apraglutidey. It was agreed his declarations would not prevent Dr Gabe from providing expert advice to the committee.
* Nominated patient expert Carolyn Wheatley declared financial interests as she has received fees from Takeda global for being a patient expert on the ATLAS project, she confirmed this ceased in 2021, Carolyn also noted that her organisation PINNT has an unrestricted grant from Takeda to support operational costs. It was agreed her declarations would not prevent Carolyn from providing expert advice to the committee.
* No further conflicts were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Richard Ballerand, Andrew Champion, and Dr Mohit Sharma.
	1. Part 2a – Closed session (experts, company representatives and members of the public, were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10842>

### Appraisal of pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor Samreen Ahmed declared direct financial interests as she has received consultancy, lecture fees and travel grants from Merck Sharp & Dohme. It was agreed her declaration would not prevent Professor Ahmed from providing expert advice to the committee.
* Nominated patient expert Holly Heath declared indirect interests as her organisation Breast Cancer Now has received funding from comparator companies Roche and Pfizer, she noted that they have not received any funding in the last 12 months Merck Sharp & Dohme. It was agreed that her declarations would not prevent Holly from providing expert advice to the committee.
* No further conflicts were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Richard Ballerand, Dr Rita Faria, and Professor Khalida Ismail.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10417>

### Appraisal of nivolumab with platinum and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or osophageal adenocarcinoma [ID1465]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bristol-Myers Squibb.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor Wasat Mansoor declared financial interests as he has received advisory board fees from Bristol-Myers Squibb. It was agreed his declaration would not prevent Professor Mansoor from providing expert advice to the committee.
* Nominated clinical expert Dr Elizabeth Smyth declared financial interests as she has received honoraria, advisory board fees and travel support from Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks. She also declared an indirect interest for funding from BMS to the Southampton Clinical Trials Unit for the ELEVATE trial. It was agreed her declaration would not prevent Dr Smyth from providing expert advice to the committee.
* No further conflicts were declared for this appraisal.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10352>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 15 March 2022 and will start promptly at 09:30am.